Journal of Oncology / 2009 / Article / Tab 1

Review Article

Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers

Table 1

Selected clinical trials of erlotinib. NSCLC, Non-small cell lung cancer; OS, overall survival; ORR, overall response rate.

MalignancyRegimenNumber of patientsResultsComments

NSCLCErlotinib vs. placebo [14]731 pts Stage IIIB/IV NSCLC after failure with first-line or second-line chemotherapyErlotinib: ORR (8.9%) OS (6.7 mo) Placebo: ORR (<1%) OS (4.7 mo)Significant improvement in OS ( )

NSCLCCarboplatin, Paclitaxel +/ Erlotinib [11]1059 pts Previously untreated stage IIIB/IV NSCLCErolotinib: ORR (21.5%) OS (10.6 mo) Placebo: ORR (19.3%) OS (10.5 mo)No difference in ORR or OS with the combination of Erlotinib and chemotherapy

Pancreatic cancerGemcitibine, Erlotinib vs. placebo [15]569 pts Unresectable, locally advanced or metastatic pancreatic cancerErlotinib: OS (6.2 mo) Placebo: OS (5.9 mo)One year survival was greater with erlotinib plus gemcitabine (23% vs. 17%; )

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.